Transfusion and Apheresis Science
Volume 42, Issue 1 , Pages 63-70 , February 2010

Novel and unexpected clearance mechanisms for cold platelets

  • Viktoria Rumjantseva
    • ,
  • Karin M. Hoffmeister

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Division of Translational Medicine, Brigham and Women’s Hospital, 1 Blackfan Circle, KARP 6, Boston, MA 02115, USA. Tel.: +1 617 355 9010; fax: +1 617 355 9016.

References 

  1. Wallace E, et al. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion. 1993;33:139–144
  2. Murphy S, Gardner F. Effect of storage temperature on maintenance of platelet viability – deleterious effect of refrigerated storage. N Engl J Med. 1969;280:1094–1098
  3. Becker G, et al. Studies of platelet concentrates stored at 22°C and 4°C. Transfusion. 1973;13:61–68
  4. Slichter S, Harker L. Preparation and storage of platelet concentrates II. Storage variables influencing platelet viability and function. Br J Haematol. 1976;34:403–419
  5. Valeri CR. Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med. 1974;290(7):353–358
  6. Kuehnert M, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41(12):1493–1499
  7. Currie L, et al. Inhibition of cytokine accumulation and bacterial growth during storage of platelet concentrates at 4°C with retention of in vitro functional activity. Transfusion. 1997;37(1):18–24
  8. Snyder E, Rinder H. Platelet storage-time to come in from the cold?. N Engl J Med. 2003;348(20):2032–2033
  9. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev. 2005;18(1):195–204
  10. AuBuchon JP, et al. Preliminary validation of a new standard of efficacy for stored platelets. Transfusion. 2004;44(1):36–41
  11. van Rhenen D, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426–2433
  12. Murphy S. What’s so bad about old platelets?. Transfusion. 2002;42(7):809–811
  13. Murphy S, Gardner FH. Platelet storage at 22°C: role of gas transport across plastic containers in maintenance of viability. Blood. 1975;46(2):209–218
  14. White J. Ultrastructural changes in stored platelets. Blood Cells. 1992;18:461–475
  15. Gulliksson H, et al. Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang. 2003;85(3):199–205
  16. Murphy S. The efficacy of synthetic media in the storage of human platelets for transfusion. Transfus Med Rev. 1999;13(3):153–163
  17. Gulliksson H. Defining the optimal storage conditions for the long-term storage of platelets. Transfus Med Rev. 2003;17(3):209–215
  18. van der Meer PF. Platelet additive solutions: a future perspective. Transfus Clin Biol. 2007;14(6):522–525
  19. Administration, F.a.D. Guidance for industry for platelet testing and evaluation of platelet substitute products draft guidance. Rockville, MD; 1999. p. 1–7.
  20. Murphy S, et al. In vitro assessment of the quality of stored platelet concentrates. The BEST (biomedical excellence for safer transfusion) task force of the international society of blood transfusion. Transfus Med Rev. 1994;8(1):29–36
  21. Ishida A, et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation – a prospective analysis. Transfusion. 1998;38(9):839–847
  22. Rebulla P, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337(26):1870–1875
  23. Wandt H, et al. Safety and cost effectiveness of a 10×10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20×10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91(10):3601–3606
  24. Murphy S, Gardner FH. Platelet storage at 22°C; metabolic, morphologic, and functional studies. J Clin Invest. 1971;50(2):370–377
  25. Holme S, Heaton WA, Whitley P. Platelet storage lesions in second-generation containers: correlation with in vivo behavior with storage up to 14 days. Vox Sang. 1990;59(1):12–18
  26. Slichter S, Harker L. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol. 1976;34:395–402
  27. Schlichter S, Harker L. Preparation and storage of platelet concentrates II. Storage variables influencing platelet viability and function. Br J Haematol. 1976;34:403–419
  28. Murphy S, Gardner FH. The effect of temperature on platelet viability. Vox Sang. 1969;17(1):22
  29. Rock G, Figueredo A. Metabolic changes during platelet storage. Transfusion. 1976;16(6):571–579
  30. Slichter SJ. In vitro measurements of platelet concentrates stored at 4 and 22°C: correlation with posttransfusion platelet viability and function. Vox Sang. 1981;40(Suppl. 1):72–86
  31. Rinder H, Snyder E. Activation of platelet concentrate during preparation and storage. Blood Cells. 1992;18(3):445–456
  32. Rinder HM, Ault KA. Platelet activation and its detection during the preparation of platelets for transfusion. Transfus Med Rev. 1998;12(4):271–287
  33. Rinder H, et al. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion. 1991;31(5):409–414
  34. Triulzi D, Kickler T, Braine H. Detection and significance of α granule membrane protein 140 expression on platelets collected by apheresis. Transfusion. 1992;32(6):529–533
  35. Fijnheer R, et al. Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion. 1990;30(1):20–25
  36. Snyder EL, et al. Occurrence of the release reaction during preparation and storage of platelet concentrates. Vox Sang. 1981;41(3):172–177
  37. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion. 2003;43(4):526–535
  38. Zucker M, Borrelli J. Reversible alteration in platelet morphology produced by anticoagulants and by cold. Blood. 1954;28:524–534
  39. Babic A, et al. In vitro function and phagocytosis of galactosylated platelet concentrates following long-term refrigeration. Transfusion. 2006;47(3):442–451
  40. Hoffmeister K, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;10(112):87–97
  41. Leytin V, et al. Role of platelet surface glycoprotein Ibα and P-selectin in the clearance of transfused platelet concentrates. Transfusion. 2004;44(10):1487–1495
  42. Sandgren P, et al. Storage of buffy-coat-derived platelets in additive solutions at 4°C and 22°C: flow cytometry analysis of platelet glycoprotein expression. Vox Sang. 2007;93(1):27–36
  43. Berger G, Hartwell D, Wagner P. P-selectin and platelet clearance. Blood. 1998;92:4446–4452
  44. Michelson A, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA. 1996;93:11877–11882
  45. Reimers HJ, et al. In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemost. 1976;35(1):151–166
  46. Italiano JJ, et al. Mechanisms and implications of platelet discoid shape. Blood. 2003;101:4789–4796
  47. Valeri C, et al. Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(β-aminoethyl ether) N,N′-tetraacetic acid–AM on the survival and function of autologous baboon platelets stored at 4°C for as long as 5days. Transfusion. 2004;44(6):865–870
  48. Winokur R, Hartwig J. Mechanism of shape change in chilled human platelets. Blood. 1995;85:1796–1804
  49. Scharf R, Hanfland P. Platelet storage lesions: analysis of platelet membrane glycoproteins and platelet-derived microparticles by fluorescence-activated flow cytometry. Transfus Sci. 1993;14:189–194
  50. Wandall HH, et al. Galactosylation does not prevent the rapid clearance of long-term, 4°C-stored platelets. Blood. 2008;111(6):3249–3256
  51. Dijkstra-Tiekstra MJ, Pietersz RN, Huijgens PC. Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters. Vox Sang. 2004;87(4):257–263
  52. Holme S, et al. The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion. 1997;37(1):12–17
  53. Kim B, Baldini M. The platelet response to hypotonic shock. Its value as an indicator of platelet viability after storage. Transfusion. 1974;14(2):130–138
  54. Murphy S, Gardner FS. Room temperature storage of platelets. Transfusion. 1976;16(1):2–3
  55. Kattlove HE. Platelet preservation – what temperature? A rationale for strategy. Transfusion. 1974;14(4):328–330
  56. Kattlove HE, Alexander B, White F. The effect of cold on platelets II. Platelet function after short-term storage at cold temperatures. Blood. 1972;40(5):688–696
  57. Eriksson L, et al. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets Comparison between platelet concentrates derived from pooled buffy coats and apheresis. Vox Sang. 1996;70(2):69–75
  58. Salama ME, et al. Platelet function testing to assess effectiveness of platelet transfusion therapy. Transfus Apher Sci. 2004;30(2):93–100
  59. Jilma-Stohlawetz P, et al. Impaired platelet function among platelet donors. Thromb Haemost. 2001;86(3):880–886
  60. Harrison P, et al. High incidence of defective high-shear platelet function among platelet donors. Transfusion. 2004;44(5):764–770
  61. Silva VA, Miller WV. Platelet transfusion survey in a regional blood program. Transfusion. 1977;17(3):255–260
  62. Handin R, Valeri C. Hemostatic effectiveness of platelets stored at 22°C. N Engl J Med. 1971;285:538–543
  63. Valeri CR. Circulation and hemostatic effectiveness of platelets stored at 4°C or 22°C: studies in aspirin-treated normal volunteers. Transfusion. 1976;16(1):20–23
  64. Filip D, Aster R. Relative hemostatic effectiveness of human platelets stored at 4°C and 22°C. J Lab Clin Med. 1978;91:618–624
  65. Hoffmeister K, et al. Glycosylation restores survival of chilled blood platelets. Science. 2003;301(5639):1531–1534
  66. Josefsson E, et al. The macrophage αMβ2 integrin αM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem. 2005;280(18):18025–18032
  67. Badlou B, et al. Role of glycoprotein Ibα in phagocytosis of platelets by macrophages. Transfusion. 2006;46(12):2090–2099
  68. Valeri C, et al. Circulation and distribution of autotransfused fresh, liquid-preserved and cryopreserved baboon platelets. Vox Sang. 2002;83(4):347–351
  69. Rumjantseva V, Grewal PK, Wandall HH, Josefsson EC, Sørensen AL, Larson G, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med, in press.
  70. van Rooijen N, van Kesteren-Hendrikx E. “In vivo” depletion of macrophages by liposome-mediated “suicide”. Methods Enzymol. 2003;373:3–16
  71. Grewal PK, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14(6):648–655
  72. Sorensen AL, et al. Role of sialic acid for platelet lifespan: exposure of β-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009;
  73. Tsuji T, Osawa T. The carbohydrate moiety of human platelet glycocalicin: the structures of the major Asn-linked sugar chains. J Biochem. 1987;101(1):241–249
  74. Berndt M, et al. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. Eur J Biochem. 1985;151(3):637–649
  75. Ellies L, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA. 2002;99(15):10042–10047
  76. Cazenave JP, Davis K, Corash L. Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Semin Hematol. 2001;38(4 Suppl. 11):46–54
  77. McCullough J, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104(5):1534–1541

PII: S1473-0502(09)00176-1

doi: 10.1016/j.transci.2009.10.008

Transfusion and Apheresis Science
Volume 42, Issue 1 , Pages 63-70 , February 2010

Article Tools

* Image Usage & Resolution